Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Leigh Ann Pansch

Nurse Practitioner, Family Dayton, OH Nurse Practitioner

NPI 1104138601 CMS profile 11123348

5300 Far Hills Ave, Dayton, OH 45429

Open in the dashboard

General payments

$669,645

2,129 records reported · program years 2021–2025

Research payments

$7,066

Paid to them · 2 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leigh Ann Pansch of Dayton, OH is reported in the CMS Open Payments database as having received $669,645 across 2,129 general payments and $7,066 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $193,126 519
2025 Research $7,066 2
2024 General $192,710 574
2023 General $162,267 475
2022 General $83,469 344
2021 General $38,073 217

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leigh Ann Pansch
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Leigh Ann Pansch were reported at $193,126. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Leigh Ann Pansch Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $38,073 $124 $35–$379 $132
2022 $83,469 $141 $44–$430 $149
2023 $162,267 $154 $49–$476 $160
2024 $192,710 $165 $51–$504 $164
2025 $193,126 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $139,238 343 payments
  2. Janssen Biotech, Inc. $97,229 229 payments
  3. UCB, Inc. $68,640 180 payments
  4. Regeneron Healthcare Solutions, Inc. $58,385 203 payments
  5. E.R. Squibb & Sons, L.L.C. $43,596 150 payments
  6. AbbVie, Inc. $41,899 254 payments
  7. Genzyme Corporation $31,856 69 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $28,638 37 payments
  9. Arcutis Biotherapeutics, Inc. $26,735 87 payments
  10. Galderma Laboratories, L.P. $23,895 53 payments
  11. Other $109,535 524 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $380,993 299 payments
  2. Consulting Fee $162,341 129 payments
  3. Travel and Lodging $76,390 296 payments
  4. Food and Beverage $46,257 1,387 payments
  5. Honoraria $2,980 3 payments
  6. Education $685 15 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $105,851 213 payments
  2. Bimzelx $49,054 123 payments
  3. TALTZ $44,984 138 payments
  4. RINVOQ $37,544 139 payments
  5. SOTYKTU $37,161 132 payments
  6. EBGLYSS $36,230 77 payments
  7. OLUMIANT $31,033 77 payments
  8. DUPIXENT Immunology $29,850 66 payments
  9. DUPIXENT Inflammation And Immunology $29,456 108 payments
  10. DUPIXENT Immunology And Inflammation $29,102 97 payments
  11. Other $153,670 977 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Regeneron Pharmaceuticals, Inc. $7,066 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

564

Median for Nurse Practitioner: 389

Drug cost

$56,056

Median for Nurse Practitioner: $21,885

Branded share of claims

7.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 11 $41,114
Metronidazole Generic 85 $4,000
Fluorouracil Generic 28 $2,521
Clobetasol Propionate Generic 36 $2,436
Ciclopirox Ciclopirox Olamine Brand 33 $1,890
Triamcinolone Acetonide Generic 147 $1,566
Ketoconazole Generic 96 $1,227
Doxycycline Hyclate Generic 14 $293
Hydrocortisone Generic 29 $279
Mupirocin Generic 45 $272

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$72,861

Medicare's payments for the services billed

Medicare patients

592

Average age 73

Services billed

2,409

343 women, 249 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 42%
Ischemic heart disease 23%
Diabetes 21%
Chronic kidney disease 16%
Atrial fibrillation 15%
Cancer 15%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$28,186 — —
Bimzelx
$18,266 — —
SOTYKTU
$17,046 — —
DUPIXENT
$14,363 11 —
TALTZ
$12,733 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

2,131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record